Why is ARVN down?
Down 6% on Nov 3, and still 9% under its Nov 2 close.
- Its Nov 3 results:
−3Long-term trend
Down 6% on Nov 3, and still 9% under its Nov 2 close.
−3Long-term trend
Follow ARVN's trial news. Pro members can get an alert when Arvinas files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Sales down 12% on the year |
| Latest filing | 8-K, Nov 3 |
Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.
Expected to report Tue Feb 23, before the open
1 more date ahead: the conference, for Pro members.
The company says its cash lasts into the second half of 2028 (8-K, Nov 3).
An officer, David K. Loomis, sold 232 shares on Nov 9, under a planned sale. 19 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ARVN is #74 of 89 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 74 |
Expected to report Tue Feb 23, before the open (in 99 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.82 a share, from $0.48.
“The decrease in R&D expenses of $17.8 million for the quarter was primarily due to a decrease in external expenses of $10.5 million, and a decrease in compensation and related personnel expenses of $6.5 million, which are not allocated by program.”
ARVN's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Sales grew 26% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 12% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | -8.1% | -5.7% | -10.1% |
| Aug 4, 2026 | +3.4% | +11.7% | +11.5% |
| May 12, 2026 | +1.8% | -0.9% | -9.1% |
Sales grew in four of the last seven years, to $263M in 2025. It lost money in each of the eight years.
RSI 42.3, MACD below signal, below both averages. Not scored.
One insider sold $20K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ARVN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products.”
ARVN scores -4 today, which Breakaway calls Poor. It is #74 of 89 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 6% on Nov 3, and still 9% under its Nov 2 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ARVN scores -4 today, which Breakaway calls Poor (below zero). That is #74 of 89 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ARVN's -4.
One insider sold $20K across 1 filing in the last 6 months. No open-market buys on record. The newest is Randy Teel, President and CEO, who sold $20K on May 21.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.